Despite the high diversification of heavy chain complementarity-determining region 3 (HCDR3) in approximately 30–35% of CLL patients, the skewed usage of IGHV in the CLL BCR repertoire has been identified [24, 42]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.